My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Sanofi - American Depositary Shares (NQ:SNY)

51.78 -0.36 (-0.69%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

39 40 Next >

Looking Into Sanofi's Recent Short Interest ↗

August 08, 2023

Via Benzinga

As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab? ↗

August 08, 2023

Tiziana Life Sciences, Inc.

Via Benzinga

Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon ↗

August 03, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary...

Via Benzinga

Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist

August 01, 2023

Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.

Via MarketBeat

Topics Artificial Intelligence

The Top Healthcare Stocks to Buy With $100 ↗

July 30, 2023

There's no need to have a fortune to invest in stocks.

Via The Motley Fool

Sanofi (SNY) Q2 2023 Earnings Call Transcript ↗

July 28, 2023

SNY earnings call for the period ending June 30, 2023.

Via The Motley Fool

Sanofi's Earnings Outlook ↗

July 27, 2023

Via Benzinga

How Is The Market Feeling About Sanofi? ↗

July 20, 2023

Via Benzinga

iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories ↗

July 28, 2023

Bloomberg

Via Benzinga

Sanofi Reports Lower Q2 Earnings, But Lifts 2023 Outlook On New Drug Launches ↗

July 28, 2023

Sanofi SA (NASDAQ: SNY) reported a 1% decline in Q2 business operating in

Via Benzinga

US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon ↗

July 28, 2023

Stocks appear to have shaken off Thursday's negativity and are positioned for a rebound on upbeat earnings.

Via Benzinga

Looking Into Sanofi's Recent Short Interest ↗

July 03, 2023

Via Benzinga

Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 28, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Earnings Scheduled For July 28, 2023 ↗

July 28, 2023

Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion.

Via Benzinga

Exscientia is the Sniper of the AI Drug Discovery Industry

July 27, 2023

News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion

Via MarketBeat

Topics Artificial Intelligence

Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports ↗

July 26, 2023

The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss...

Via Benzinga

7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023 ↗

July 23, 2023

Even some of the top players of the market don’t get the attention they deserve, making these blue-chip stocks compelling.

Via InvestorPlace

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

July 20, 2023

From Recludix Pharma, Inc.

Via GlobeNewswire

NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories ↗

July 18, 2023

Wall Street Journal

Via Benzinga

AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants ↗

July 18, 2023

The FDA approved AstraZeneca Plc (NASDAQ:

Via Benzinga

Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗

July 17, 2023

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in...

Via Benzinga

Is Affordable Insulin Available? Survey Reveals Uninsured Americans Paying More Despite Promised Price Reduction ↗

July 13, 2023

According to a survey conducted by U.S.

Via Benzinga

Why Shares of Exscientia Jumped on Wednesday ↗

July 12, 2023

The company may be riding the wave of an AI healthcare boom.

Via The Motley Fool

Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement ↗

July 12, 2023

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily

Via Benzinga

Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA) ↗

July 10, 2023

Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its breakt

Via Benzinga

Evotec Secures US Government Contract For Orthopoxvirus Antibody ↗

July 05, 2023

The U.S.

Via Benzinga

First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California ↗

July 03, 2023

The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs.

Via Benzinga

Sanofi's Amlitelimab Hits Primary Goal In Mid-Stage Atopic Dermatitis Study ↗

June 27, 2023

Sanofi SA (NASDAQ: SNY) says its Phase 2b study (STREAM-AD) of amlitelimab for adults with moderate-to-severe atopic dermatitis, who cannot adequately manage their condition with topical medications,...

Via Benzinga

AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News ↗

June 23, 2023

The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues.

Via Investor's Business Daily

GSK Confidentially Settles First Zantac-Associated Cancer Lawsuit Due For US Trial Next Month ↗

June 23, 2023

GSK plc (NYSE: GSK) has reached a confidential settlement with James Goet

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

39 40 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.